Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Melanoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 48 articles:
HTML format



Single Articles


    July 2022
  1. ARANCE A, de la Cruz-Merino L, Petrella TM, Jamal R, et al
    Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
    J Clin Oncol. 2022 Jul 22:JCO2200221. doi: 10.1200/JCO.22.00221.
    PubMed     Abstract available


  2. DUMMER R, Flaherty KT, Robert C, Arance A, et al
    COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.
    J Clin Oncol. 2022 Jul 21:JCO2102659. doi: 10.1200/JCO.21.02659.
    PubMed     Abstract available


  3. SULLIVAN RJ
    What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma?
    J Clin Oncol. 2022 Jul 21:JCO2201066. doi: 10.1200/JCO.22.01066.
    PubMed    


  4. MONCRIEFF MD, Lo SN, Scolyer RA, Heaton MJ, et al
    Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
    J Clin Oncol. 2022 Jul 18:JCO2102488. doi: 10.1200/JCO.21.02488.
    PubMed     Abstract available


    June 2022
  5. GARBE C, Keim U, Amaral T, Berking C, et al
    Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
    J Clin Oncol. 2022 Jun 16:JCO2200202. doi: 10.1200/JCO.22.00202.
    PubMed     Abstract available


  6. SETH R, Messersmith H, Funchain P
    Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2022 Jun 3:JCO2200944. doi: 10.1200/JCO.22.00944.
    PubMed     Abstract available


    March 2022
  7. OLIVIER T, Prasad V
    Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.
    J Clin Oncol. 2022 Mar 8:JCO2102904. doi: 10.1200/JCO.21.02904.
    PubMed    


  8. CARVAJAL RD, Nathan P, Sacco JJ, Orloff M, et al
    Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.
    J Clin Oncol. 2022 Mar 7:JCO2101805. doi: 10.1200/JCO.21.01805.
    PubMed     Abstract available


    February 2022
  9. PIRES DA SILVA I, Ahmed T, McQuade JL, Nebhan CA, et al
    Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
    J Clin Oncol. 2022 Feb 10:JCO2101701. doi: 10.1200/JCO.21.01701.
    PubMed     Abstract available


    January 2022
  10. CALLAHAN MK, Chapman PB
    PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2102801. doi: 10.1200/JCO.21.02801.
    PubMed    


  11. DUMMER R, Long GV, Robert C, Tawbi HA, et al
    Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
    J Clin Oncol. 2022 Jan 14:JCO2101601. doi: 10.1200/JCO.21.01601.
    PubMed     Abstract available


    December 2021
  12. POSTOW MA, Goldman DA, Shoushtari AN, Betof Warner A, et al
    Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
    J Clin Oncol. 2021 Dec 20:JCO2101570. doi: 10.1200/JCO.21.01570.
    PubMed     Abstract available


    November 2021
  13. WOLCHOK JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al
    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    J Clin Oncol. 2021 Nov 24:JCO2102229. doi: 10.1200/JCO.21.02229.
    PubMed     Abstract available


    August 2021
  14. ANDTBACKA RHI, Curti B, Daniels GA, Hallmeyer S, et al
    Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
    J Clin Oncol. 2021 Aug 31:JCO2003246. doi: 10.1200/JCO.20.03246.
    PubMed     Abstract available


    July 2021
  15. DIAB A, Tykodi SS, Daniels GA, Maio M, et al
    Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
    J Clin Oncol. 2021 Jul 13:JCO2100675. doi: 10.1200/JCO.21.00675.
    PubMed     Abstract available


    June 2021
  16. HUPPERT LA, Daud AI
    Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma.
    J Clin Oncol. 2021 Jun 17:JCO2100943. doi: 10.1200/JCO.21.00943.
    PubMed    


  17. CHAPMAN PB
    Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
    J Clin Oncol. 2021 Jun 4:JCO2101012. doi: 10.1200/JCO.21.01012.
    PubMed    


    May 2021
  18. SARNAIK AA, Hamid O, Khushalani NI, Lewis KD, et al
    Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
    J Clin Oncol. 2021 May 12:JCO2100612. doi: 10.1200/JCO.21.00612.
    PubMed     Abstract available


  19. OLSON DJ, Eroglu Z, Brockstein B, Poklepovic AS, et al
    Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
    J Clin Oncol. 2021 May 4:JCO2100079. doi: 10.1200/JCO.21.00079.
    PubMed     Abstract available


    February 2021
  20. EL SHAROUNI MA, Ahmed T, Varey AHR, Elias SG, et al
    Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.
    J Clin Oncol. 2021 Feb 18:JCO2002446. doi: 10.1200/JCO.20.02446.
    PubMed     Abstract available


    January 2021
  21. SHOUSHTARI AN
    Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003523. doi: 10.1200/JCO.20.03523.
    PubMed    


  22. HINDIE E
    Considerations on the Role of Pembrolizumab Adjuvant Therapy in AJCC-8 Stage IIIA Melanoma.
    J Clin Oncol. 2021 Jan 25:JCO2003213. doi: 10.1200/JCO.20.03213.
    PubMed    


  23. YAN X, Sheng X, Chi Z, Si L, et al
    Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.
    J Clin Oncol. 2021 Jan 14:JCO2000902. doi: 10.1200/JCO.20.00902.
    PubMed     Abstract available


  24. PIULATS JM, Espinosa E, de la Cruz Merino L, Varela M, et al
    Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    J Clin Oncol. 2021 Jan 8:JCO2000550. doi: 10.1200/JCO.20.00550.
    PubMed     Abstract available


  25. KHAN S, Carvajal RD
    Dual Immunological Checkpoint Blockade for Uveal Melanoma.
    J Clin Oncol. 2021 Jan 8:JCO2003274. doi: 10.1200/JCO.20.03274.
    PubMed    


    October 2020
  26. PELSTER MS, Gruschkus SK, Bassett R, Gombos DS, et al
    Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
    J Clin Oncol. 2020 Oct 30:JCO2000605. doi: 10.1200/JCO.20.00605.
    PubMed     Abstract available


    September 2020
  27. ROBERT C, Long GV, Brady B, Dutriaux C, et al
    Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
    J Clin Oncol. 2020 Sep 30:JCO2000995. doi: 10.1200/JCO.20.00995.
    PubMed     Abstract available


  28. EGGERMONT AMM, Blank CU, Mandala M, Long GV, et al
    Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    J Clin Oncol. 2020 Sep 18:JCO2002110. doi: 10.1200/JCO.20.02110.
    PubMed     Abstract available


    July 2020
  29. KARAKOUSIS G, Sondak VK, Zager JS
    Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas.
    J Clin Oncol. 2020 Jul 23:JCO2001686. doi: 10.1200/JCO.20.01686.
    PubMed    


  30. OLOFSSON BAGGE R, Kicinski M, Faries MB, Gyorki DE, et al
    Comment on "Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram".
    J Clin Oncol. 2020 Jul 23:JCO2001680. doi: 10.1200/JCO.20.01680.
    PubMed    


  31. HINDIE E
    Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim.
    J Clin Oncol. 2020 Jul 23:JCO2001199. doi: 10.1200/JCO.20.01199.
    PubMed    


    June 2020
  32. LO SN, Ma J, Scolyer RA, Haydu LE, et al
    Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.
    J Clin Oncol. 2020 Jun 12:JCO1902362. doi: 10.1200/JCO.19.02362.
    PubMed     Abstract available


  33. GARBE C, Keim U, Suciu S, Amaral T, et al
    Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
    J Clin Oncol. 2020 Jun 12:JCO1903034. doi: 10.1200/JCO.19.03034.
    PubMed     Abstract available


    May 2020
  34. FARIES MB
    Improved Tool for Predicting Sentinel Lymph Node Metastases in Melanoma.
    J Clin Oncol. 2020 May 28:JCO2001121. doi: 10.1200/JCO.20.01121.
    PubMed    


    April 2020
  35. TAYLOR MH, Lee CH, Makker V, Rasco D, et al
    Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    J Clin Oncol. 2020;38:1154-1163.
    PubMed     Abstract available


    March 2020
  36. SETH R, Messersmith H, Kaur V, Kirkwood JM, et al
    Systemic Therapy for Melanoma: ASCO Guideline.
    J Clin Oncol. 2020 Mar 31:JCO2000198. doi: 10.1200/JCO.20.00198.
    PubMed     Abstract available


  37. MAURICHI A, Miceli R, Eriksson H, Newton-Bishop J, et al
    Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram.
    J Clin Oncol. 2020 Mar 13:JCO1901902. doi: 10.1200/JCO.19.01902.
    PubMed     Abstract available


    February 2020
  38. DAVIES MA
    Is It Safe to Stop Anti-PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?
    J Clin Oncol. 2020 Feb 25:JCO2000136. doi: 10.1200/JCO.20.00136.
    PubMed    


  39. BETOF WARNER A, Palmer JS, Shoushtari AN, Goldman DA, et al
    Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
    J Clin Oncol. 2020 Feb 13:JCO1901464. doi: 10.1200/JCO.19.01464.
    PubMed     Abstract available


    January 2020
  40. HAYDU LE, Lo SN, McQuade JL, Amaria RN, et al
    Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.
    J Clin Oncol. 2020 Jan 28:JCO1901508. doi: 10.1200/JCO.19.01508.
    PubMed     Abstract available


    December 2019
  41. BETOF WARNER A, Postow MA
    Another Victory for Immune Checkpoint Blockade in Melanoma: Adjuvant Ipilimumab Over Interferon.
    J Clin Oncol. 2019 Dec 27:JCO1902988. doi: 10.1200/JCO.19.02988.
    PubMed    


  42. TARHINI AA, Lee SJ, Hodi FS, Rao UNM, et al
    Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
    J Clin Oncol. 2019 Dec 27:JCO1901381. doi: 10.1200/JCO.19.01381.
    PubMed     Abstract available


    October 2019
  43. MENZER C, Menzies AM, Carlino MS, Reijers I, et al
    Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.
    J Clin Oncol. 2019 Oct 3:JCO1900489. doi: 10.1200/JCO.19.00489.
    PubMed     Abstract available


    September 2019
  44. LEITER U, Stadler R, Mauch C, Hohenberger W, et al
    Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
    J Clin Oncol. 2019 Sep 26:JCO1802306. doi: 10.1200/JCO.18.02306.
    PubMed     Abstract available


  45. HONG AM, Fogarty GB, Dolven-Jacobsen K, Burmeister BH, et al
    Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2019 Sep 25:JCO1901414. doi: 10.1200/JCO.19.01414.
    PubMed     Abstract available


    May 2019
  46. LONG GV, Dummer R, Schadendorf D, Santinami M, et al
    Reply to E. Hindie and K.R. Hess.
    J Clin Oncol. 2019;37:1356-1358.
    PubMed    


    April 2019
  47. KLUGER HM, Margolin KA, Davies MA, Long GV, et al
    Reply to A. Shinde et al.
    J Clin Oncol. 2019;37:1031-1032.
    PubMed    


  48. BAE JM, Chung KY, Yun SJ, Kim H, et al
    Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study.
    J Clin Oncol. 2019;37:903-911.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: